Clinical trials: Borderline Resectable Pancreatic Cancer, open to volunteers
Pancreatic Cancer Resectable
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
The goal of this clinical trial is to learn if surufatinib (VEGFR-TKI) plus toripalimab (PD-1 inhibitor) and mFOLFIRINOX (chemotherapy) works as neoadjuvant therapy for patients with high-risk or borderline resectable pancreatic…
- Trial name
- NCT07469956
- Testing
- Surufatinib, Toripalimab, mFOLFIRINOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Since patients with (borderline) resectable pancreatic cancer have a limited life expectancy, it is important to improve treatment strategies.
- Conditions
- Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
- Trial name
- PREOPANC-5 (NCT06384560)
- Testing
- Pembrolizumab, Folfirinox, SABR
- Where
- 4 sites in Netherlands
- Volunteers
- 66 people
- Sponsor
- Amsterdam UMC, location VUmc
Pancreatic Cancer
Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Oncolytic virus Plus Anti-PD1 and Chemotherapy as Preoperative therapy for Patients with Borderline Resectable and Locally…
- Trial name
- NCT06346808
- Testing
- Oncolytic virus Plus Anti-PD1 and Chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan University
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
This phase II trial tests how well gemcitabine, cisplatin and nab-paclitaxel given before surgery (neoadjuvant) works in treating patients with pancreatic cancer that can be removed by surgery (resectable) or that is borderline…
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8
- Trial name
- NCT06423326
- Testing
- Biopsy, Biospecimen Collection, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Georgetown University
Pancreatic Cancer
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
The purpose of this study is to assess surgical conversion rate and the immediate and long-term outcomes to patients who receive hypofractionated radiotherapy and AG combined with camrelizumab immunotherapy of Borderline…
- Trial name
- NCT06435260
- Testing
- Camrelizumab+chemotherapy, hypofractionated radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hebei Medical University Fourth Hospital
Pancreatic Cancer, Borderline Resectable Pancreatic Cancer
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer
The purpose of this Interventional clinical trial is to evaluate safety and efficacy of 'IMD10 (focused ultrasound)' in the treatment of borderline resectable pancreatic cancer or locally advanced pancreatic cancer.
- Conditions
- Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer
- Trial name
- SonoPANIII (NCT07325214)
- Testing
- IMD10, chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin]
- Where
- 5 sites in United States, South Korea
- Volunteers
- 360 people
- Sponsor
- IMGT Co., Ltd.
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- ACCELERATE (NCT06574620)
- Testing
- Genetic testing, Optional biopsy, Tissue collection
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- British Columbia Cancer Agency
Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT06673017
- Testing
- PTM-101
- Where
- 9 sites in United States, Australia
- Volunteers
- 26 people
- Sponsor
- PanTher Therapeutics
Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
The purpose of this research is to investigate the activity and safety of the combination of gemcitabine plus nab-paclitaxel and sintilimab as neoadjuvant therapy in treating patients with resectable and borderline resectable…
- Conditions
- Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB, Pancreatic Cancer Stage III
- Trial name
- NCT05562297
- Testing
- sintilimab, nab-paclitaxel, gemcitabine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Pancreatic Cancer
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
The researchers are doing this study to find out whether ELI-002 7P in combination with mFOLFIRINOX, with or without tislelizumab, is a safe treatment approach in people who have pancreatic ductal adenocarcinoma (PDAC) with a…
- Trial name
- NCT07671339
- Testing
- ELI-002 7P, Tislelizumab, mFOLFIRINOX
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma
IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
This study is a Phase II trial evaluating the safety and efficacy of IBI343 in combination with chemotherapy as neoadjuvant therapy for subjects with borderline resectable pancreatic cancer (BRPC).
- Trial name
- NCT07415525
- Testing
- IBI343
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Pancreas Cancer
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
The primary objective of this study is to assess the impact of bethanechol therapy on R0 resection rates. The safety objective will be assessment of the safety and tolerability of bethanechol in combination with gemcitabine and…
- Trial name
- NCT05241249
- Testing
- Bethanechol, Gemcitabine, nab-paclitaxel
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Susan E. Bates
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial
This phase II trial tests the impact of using SMAD4-mutant status to personalize chemotherapy in treating patients with pancreatic ductal adenocarcinoma (PDAC) that can be removed by surgery (resectable) or that may be between…
- Trial name
- NCT07748611
- Testing
- Biospecimen Collection, Computed Tomography, Electronic Health Record Review
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Northwestern University
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal adenocarcinoma.
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8
- Trial name
- NCT06595160
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Emory University
Pancreatic Cancer
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study
Pancreatic cancer is a highly malignant digestive system tumor with a very poor prognosis. In recent years, both the incidence and mortality rates of pancreatic cancer have shown a marked upward trend worldwide.
- Trial name
- NCT07542002
- Testing
- Irinotecan liposome, 5-fluorouracil/leucovorin, and oxaliplatin, with or without adadelimab.
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Pancreas Cancer, Lung Cancer
Stereotactic Magnetic Resonance Guided Radiation Therapy
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.
- Conditions
- Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases
- Trial name
- NCT04115254
- Testing
- MR-guided Linac
- Where
- 2 sites in United States
- Volunteers
- 397 people
- Sponsor
- Dana-Farber Cancer Institute
Locally Advanced Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma
PULSAR in Systemic Therapy for Pancreatic Cancer
Pancreatic cancer remains one of the malignancies with the lowest survival rates, largely due to late-stage diagnosis and the difficulty of achieving curative resection.
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Oligometastatic Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07269626
- Testing
- Personalized Ultrafractionated Adaptive Radiotherapy
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Samsung Medical Center
Borderline Resectable Pancreatic Adenocarcinoma
HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
This study is a Phase II clinical trial that plans to enroll 40 patients with borderline resectable pancreatic cancer harboring a KRAS G12D mutation, aiming to evaluate the efficacy of HRS-4642 in combination with Nimotuzumab and…
- Trial name
- NCT07240766
- Testing
- HRS-4642+AG+Nimotuzumab
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Pancreatic Cancer
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
The survival rate for patients with pancreatic cancer remains at a dismal 10% or less at 5 years, and although trials integrating stereotactic body radiation therapy (SBRT) alone have shown improvement in local control, initial…
- Trial name
- NCT06141031
- Testing
- TTI-101, Stereotactic body radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Pancreatic Cancer, Locally Advanced
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in borderline resectable or locally advanced pancreatic cancer.
- Trial name
- MAP-03 (NCT05802394)
- Testing
- Later-line therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital